Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

Published

Journal Article

Patients with chemorefractory non-Hodgkin lymphomas generally have a poor prognosis. We used the observational database of the Center for International Blood and Marrow Transplant Research to study the outcome of 533 patients with refractory diffuse large B cell lymphoma (DLBCL) or grade III follicular lymphoma (FL-III) who underwent allogeneic hematopoietic cell transplantation (allo-HCT) using either myeloablative (MA; n = 307) or reduced-intensity/nonmyeloablative conditioning (RIC/NST; n = 226) between 1998 and 2010. We analyzed nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Only 45% of the patients at transplantation had a Karnofsky performance score of ≥90%. Median follow-up of surviving patients after MA and RIC/NST allo-HCT is 35 months and 30 months, respectively. At 3 years, MA allo-HCT was associated with a higher NRM compared with RIC/NST (53% versus 42%; P = .03), similar PFS (19% versus 23%; P = .40), and lower OS (19% versus 28%; P = .02), respectively. On multivariate analysis, FL-III histology was associated with lower NRM (relative risk [RR], .52), reduced risk of relapse/progression (RR, .42), and superior PFS (RR, .51) and OS (RR, .53), whereas MA conditioning was associated with reduced risk of relapse/progression (RR, .66). Despite a refractory state, a small subset of DLBCL and FL-III patients can attain durable remissions after allo-HCT. Conditioning regimen intensity was not associated with PFS and OS despite a higher risk of relapse/progression with RIC/NST allo-HCT.

Full Text

Duke Authors

Cited Authors

  • Hamadani, M; Saber, W; Ahn, KW; Carreras, J; Cairo, MS; Fenske, TS; Gale, RP; Gibson, J; Hale, GA; Hari, PN; Hsu, JW; Inwards, DJ; Kamble, RT; Klein, A; Maharaj, D; Marks, DI; Rizzieri, DA; Savani, BN; Schouten, HC; Waller, EK; Wirk, B; Laport, GG; Montoto, S; Maloney, DG; Lazarus, HM

Published Date

  • May 2013

Published In

Volume / Issue

  • 19 / 5

Start / End Page

  • 746 - 753

PubMed ID

  • 23380340

Pubmed Central ID

  • 23380340

Electronic International Standard Serial Number (EISSN)

  • 1523-6536

Digital Object Identifier (DOI)

  • 10.1016/j.bbmt.2013.01.024

Language

  • eng

Conference Location

  • United States